Lipocine to continue commercialization of Tlando through Verity Pharma

Lipocine announced that commercialization of Tlando in the U.S. has been transitioned to its licensee Verity Pharma, effective February 1, enabling the continuity of patient access to Tlando. Tlando is the first and only oral testosterone replacement therapy option approved by the FDA that does not require dose titration. In January, Lipocine and Gordon Silver entered into an exclusive license agreement under which Verity Pharma will market Tlando in the U.S. and, if approved, in Canada. Under the terms of the license agreement, Lipocine has received the second tranche of the $11M license fee, $5M. In addition, per the license agreement, Gordon Silver is to make license fee payments of $2.5M and $1M no later than January 1, 2025, and January 1, 2026, respectively.